Abstract 69P
Background
While iron deficiency (ID) in cancer patients is frequent, it is likely under-diagnosed and under-treated, in particular in patients without anaemia or at an early stage of the disease. Also, ID diagnosis is rarely based on the transferrin coefficient saturation (TSAT) which is very sensitive in patients with inflammatory diseases. We previously showed that ID was frequent in patients under metastatic treatment. Here, we aimed to assess the prevalence of ID based on TSAT index in cancer patients treated at an early stage of the disease.
Methods
This is a post hoc analysis using data collected during the CARENFER study which was conducted in 15 oncology units in France in 2019. All patients present in the medical unit during the study period, regardless of the type of tumour, were eligible. Both serum ferritin and TSAT index were measured in all included patients. The prevalence of TSAT<20% was computed in two subgroups of patients receiving early treatment of the disease: either adjuvant or neo-adjuvant treatment.
Results
A total of 443 patients with a documented curative treatment were analysed: 300 (67.7%) received an adjuvant treatment and 143 (32.3%) a neo-adjuvant treatment, consisting in chemotherapy in most cases. TSAT<20% was found in 47.1% (41.5-52.8) of patients with adjuvant treatment and 51.0% (42.9-59.1) of patients with neo-adjuvant treatment. Among iron-deficient patients according to ESMO definition (based on both ferritin level and TSAT), 85.8% and 90.1% of patients had a TSAT <20%, in the two treatment groups respectively.
Conclusions
The prevalence of ID in cancer patients receiving adjuvant or neo-adjuvant treatment was high, and of the same magnitude than that reported in patients under metastatic treatment. Early diagnosis and treatment of ID in those patients at early-stage disease might limit the occurrence of anaemia and improve quality of life. TSAT < 20% as the sole criterion for defining ID had a high sensitivity and might be considered for ID diagnosis.
Clinical trial identification
NCT03924271.
Editorial acknowledgement
We thank Valérie Briand (IQVIA) for reviewing the abstract.
Legal entity responsible for the study
Vifor Pharma Group.
Funding
Vifor Pharma Group.
Disclosure
E. Luporsi-Gely: Financial Interests, Personal, Advisory Board: Janssen Oncology; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: MSD Oncology; Financial Interests, Personal, Expert Testimony: Pfizer; Non-Financial Interests, Personal, Other: Merck Serono; Non-Financial Interests, Personal, Other: Ipsen; Non-Financial Interests, Personal, Other: BMS; Non-Financial Interests, Personal, Other: MSD Oncology. A. Turpin: Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Advisory Role: Bayer; Financial Interests, Personal, Advisory Role: Merck; Financial Interests, Personal, Advisory Role: Sanofi; Financial Interests, Personal, Advisory Role: Servier; Financial Interests, Personal, Other: Mylan; Financial Interests, Personal, Other: Sanofi; Financial Interests, Personal, Other: Merck. V. Massard: Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Janssen; Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Research Grant: AstraZeneca; Financial Interests, Personal, Other: Novartis; Financial Interests, Personal, Other: Pfizer; Financial Interests, Personal, Other: AstraZeneca; Financial Interests, Personal, Other: Astellas; Financial Interests, Personal, Other: Ipsen. H. Simon: Financial Interests, Personal, Funding: Lilly; Financial Interests, Personal, Funding: Pfizer; Financial Interests, Personal, Funding: Tesaro; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Lilly; Financial Interests, Personal, Advisory Role: Vifor Pharma; Financial Interests, Personal, Advisory Role: Pierre Fabre; Financial Interests, Personal, Advisory Role: Mundipharma; Financial Interests, Personal, Advisory Role: Mylan; Financial Interests, Personal, Advisory Role: Sandoz; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Other: Roche; Financial Interests, Personal, Other: Novartis; Financial Interests, Personal, Other: AstraZeneca; Financial Interests, Personal, Other: Mundipharma; Financial Interests, Personal, Other: Pfizer; Financial Interests, Personal, Other: Lilly. A. Ruppert: Financial Interests, Personal, Advisory Role: Vifor Pharma; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Speaker’s Bureau: Vifor Pharma; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: Novartis. S. Belarbia: Financial Interests, Institutional, Full or part-time Employment: Vifor Pharma. A. Lopez: Financial Interests, Personal, Research Grant: Roche; Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Invited Speaker: Vifor Pharma; Financial Interests, Personal, Invited Speaker: Bayer; Financial Interests, Personal, Invited Speaker: Merck; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Other: AbbVie; Financial Interests, Personal, Other: MSD; Financial Interests, Personal, Other: Mundipharma; Financial Interests, Personal, Other: Ipsen; Financial Interests, Personal, Other: Novartis; Financial Interests, Personal, Other: Amgen; Financial Interests, Personal, Other: Vifor Pharma. A. Carnot: Non-Financial Interests, Institutional, Principal Investigator: Vifor Pharma; Non-Financial Interests, Institutional, Principal Investigator: BMS; Non-Financial Interests, Institutional, Principal Investigator: MSD; Non-Financial Interests, Institutional, Principal Investigator: Janssen. All other authors have declared no conflicts of interest.